Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

First in Human Clinical Trial of ApTOLL in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04742062
Recruitment Status : Completed
First Posted : February 5, 2021
Last Update Posted : February 5, 2021
Sponsor:
Collaborators:
Science and Innovation Spanish Ministry
Anagram
Information provided by (Responsible Party):
aptaTargets S.L.

Brief Summary:
This is a Phase I, first-in-human, dose ascending, randomized, placebo-controlled clinical study to assess the tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is an aptamer able to antagonize TLR4 receptor and, therefore, to reduce the inflammatory response.

Condition or disease Intervention/treatment Phase
Stroke Drug: ApTOLL Other: Placebo Phase 1

Detailed Description:

This Phase I clinical trial is divided in two parts: the first part (part A) is a single dose escalation study and the second (part B) is a multiple dose study. Both are performed in healthy volunteers.

  • First part: a single dose, i.v. administration (slow infusion), dose escalation with a maximum of 7 single dose levels, randomized, double-blind, placebo-controlled (saline solution), in healthy subjects.
  • Second part: a multiple dose, i.v. administration (slow infusion), randomized, double-blind, placebo-controlled (saline solution), in healthy subjects.

The main objectives of this study are:

  1. To evaluate the tolerability and pharmacokinetic characteristics of ApTOLL in healthy volunteers, after single dose administration in fasting conditions, following an ascending dosing scheme.
  2. To evaluate the tolerability and pharmacokinetic characteristics of ApTOLL in healthy volunteers, after multiple dose administration in fasting conditions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: First in Human Dose Ascending, Randomized, Placebo-Controlled Clinical Trial to Assess Tolerability and Pharmacokinetics of ApTOLL in Healthy Volunteers
Actual Study Start Date : July 18, 2019
Actual Primary Completion Date : February 27, 2020
Actual Study Completion Date : March 20, 2020

Arm Intervention/treatment
Active Comparator: ApTOLL single dose
ApTOLL is administered intravenously in a single ascending dose pattern in seven dose levels (0.7mg - 70mg). Levels 1 - 3 include one subject per level and levels 4 - 7 include six subjects per level (1 sentinel + 5 subjects).
Drug: ApTOLL
ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatoryy response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.

Placebo Comparator: Placebo single dose
Placebo is administered intravenously during seven dose levels. Levels 1 - 3 include one subject per level and levels 4 - 7 include two subjects per level (1 sentinel + 1 subject).
Other: Placebo
100 mL 0.9% Sodium Chloride solution

Active Comparator: ApTOLL multiple dose
ApTOLL is administered intravenously every eight hours during 24h (21mg). This arm includes six subjects (1 sentinel + 5 subjects).
Drug: ApTOLL
ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatoryy response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.

Placebo Comparator: Placebo multiple dose
Placebo is administered intravenously every eight hours during 24h. This arm includes twosubjects (1 sentinel + 1 subject).
Other: Placebo
100 mL 0.9% Sodium Chloride solution




Primary Outcome Measures :
  1. Incidence of Adverse Events as assessed by CTCAE v4.0 [ Time Frame: From dosing to follow-up (day 15 after dosing) ]
    Adverse Events that occur during the study

  2. Peak Plasma Concentration [ Time Frame: Predose and at different times up to 72 hours post-dose ]
    Peak Plasma Concentration (Cmax)

  3. Area under the plasma concentration [ Time Frame: Predose and at different times up to 72 hours post-dose ]
    Area under the plasma concentration versus time curve (AUC)


Secondary Outcome Measures :
  1. Vital signs [ Time Frame: From screening to follow-up (day 15 after dosing) ]
    Heart Rate

  2. Vital signs [ Time Frame: From screening to follow-up (day 15 after dosing) ]
    Blood Presure

  3. Vital signs [ Time Frame: From screening to follow-up (day 15 after dosing) ]
    Respiratory Rate

  4. Vital signs [ Time Frame: From screening to follow-up (day 15 after dosing) ]
    Body Temperature

  5. Laboratory determinations [ Time Frame: From screening to follow-up (day 15 after dosing) ]
    Number of patients with treatment-related alterations coagulation parameters (Protrombine Time (PT) and activated Partial Tromboplastine Time (aPTT))

  6. Laboratory determinations [ Time Frame: From screening to follow-up (day 15 after dosing) ]
    Number of patients with treatment-related alterations Complement Factors activation determined in blood



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female subjects (women without possibility of becoming pregnant) willing and able to give their written consent to participate in the trial.
  2. Healthy subjects aged within: 18 to 55 years (limits included).
  3. Clinical history and physical examination results within normality.
  4. Vital signs and electrocardiogram without clinically significant pathologic abnormalities and with QTc (Corrected QT space) values lower than 450 ms.
  5. Body weight between 65 and 85 kg, inclusive.
  6. BMI (Body Mass Index) between 19.0 and 30.0 kg/m2.
  7. No clinically significant abnormalities in haematology, biochemistry, serology (Ag HBV (Hepatitis B Virus), HCV (Hepatitis C Virus) antibodies, HIV (Human Immunodeficiency Virus) antibodies) and urine tests.

Exclusion Criteria:

  1. Any chronic medical condition (such as type 1 diabetes) requiring chronic treatment.
  2. Evidence of active infection requiring antibiotic therapy within 14 days prior to screening.
  3. Medical history of vasculitis or any autoimmune disease excluding seasonal allergic rhinitis and childhood history of atopic dermatitis.
  4. Subject having at screening examination a sitting blood pressure more than or equal to 140/90 mm Hg or lower than or equal to 90/50 mmHg.
  5. Subject having at screening examination a pulse more than 100 beats per minute or a body temperature more than 37.7 °C. or a respiratory rate outside the normal range of (14-20 breath per minute).
  6. History of any treatment for cancer within the past 2 years, other than basal cell or squamous cell carcinoma of the skin.
  7. Clinically significant abnormalities in screening laboratory tests.
  8. Any prescription, over-the-counter and herbal medications within 10 days prior to study dosing.
  9. Use of an investigational drug within 3 months prior to dosing in this study.
  10. Psychiatric history of current or past psychosis, bipolar disorder, clinical depression, or anxiety disorder requiring chronic medication within the past 5 years.
  11. Pregnant or breastfeeding women.
  12. History of substance abuse, including alcohol.
  13. Smokers.
  14. History of substance or drug dependence, or positive urine drug screen at screening visit.
  15. History of head injury.
  16. History of sensitivity to any drug.
  17. Having donated blood in the last month before start of the study.
  18. Any reason or opinion of the investigator that would prevent the subject from participation in the study.
  19. Inability to follow the instructions or an unwillingness to collaborate during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04742062


Locations
Layout table for location information
Spain
Clinical Pharmacology Department. Hospital Universitario de La Princesa
Madrid, Spain, 28006
Sponsors and Collaborators
aptaTargets S.L.
Science and Innovation Spanish Ministry
Anagram
Investigators
Layout table for investigator information
Principal Investigator: Dolores Ochoa, MD, PhD Clinical Trials Unit. Hospital Universitario La Princesa
Additional Information:
Layout table for additonal information
Responsible Party: aptaTargets S.L.
ClinicalTrials.gov Identifier: NCT04742062    
Other Study ID Numbers: ApTOLL-FIH-01
First Posted: February 5, 2021    Key Record Dates
Last Update Posted: February 5, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: All the data from this study are going to be published.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by aptaTargets S.L.:
Healthy volunteers
ApTOLL